Scolaris Content Display Scolaris Content Display

Antibiotics for secondary prevention of coronary heart disease

This is not the most recent version

References

Additional references

Al‐Younes 2016

Al‐Younes HM, Abu Abeeleh MA, Jaber BM. Lack of strong association of Chlamydia pneumoniae and atherosclerosis in a Jordanian population. Journal of Infection in Developing Countries 2016;10(5):457‐64.

Ambrose 2015

Ambrose JA, Singh M. Pathophysiology of coronary artery disease leading to acute coronary syndromes. F1000Prime Reports 2015;7:08.

Anderson 1996

Anderson R, Theron AJ, Feldman C. Membrane‐stabilizing, anti‐inflammatory interactions of macrolides with human neutrophils. Inflammation 1996;20(6):693‐705.

Anderson 1999

Anderson JL, Muhlestein JB, Carlquist J, Allen A, Trehan S, Nielson C, et al. Randomized secondary prevention trial of azithromycin in patients with coronary artery disease and serological evidence for Chlamydia pneumoniae infection: The Azithromycin in Coronary Artery Disease: Elimination of Myocardial Infection with Chlamydia (ACADEMIC) study. Circulation 1999;99(12):1540‐7.

Andraws 2005

Andraws R, Berger JS, Brown DL. Effects of antibiotic therapy on outcomes of patients with coronary artery disease: a meta‐analysis of randomized controlled trials. JAMA 2005;293(21):2641‐7.

Andriankaja 2011

Andriankaja O, Trevisan M, Falkner K, Dorn J, Hovey K, Sarikonda S, et al. Association between periodontal pathogens and risk of nonfatal myocardial infarction. Community Dentistry and Oral Epidemiology 2011;39(2):177‐85.

Assar 2015

Assar O, Nejatizadeh A, Dehghan F, Kargar M, Zolghadri N. Association of Chlamydia pneumoniae infection with atherosclerotic plaque formation. Global Journal of Health Science 2015;8(4):260‐7.

Baker 2007

Baker WL, Couch KA. Azithromycin for the secondary prevention of coronary artery disease: a meta‐analysis. American Journal of Health‐System Pharmacy 2007;64(8):830‐6.

Begg 1994

Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994;50(4):1088‐101.

Berdy 2005

Berdy J. Bioactive microbial metabolites. The Journal of Antibiotics 2005;58(1):1‐26.

Bertrand 2016

Bertrand MJ, Tardif JC. Inflammation and beyond: new directions and emerging drugs for treating atherosclerosis. Expert Opinion on Emerging Drugs 2016;22(1):1‐26.

Bloemenkamp 2003

Bloemenkamp DG, Mali WP, Visseren FL, Van der Graaf Y. Meta‐analysis of sero‐epidemiologic studies of the relation between Chlamydia pneumoniae and atherosclerosis: does study design influence results?. American Heart Journal 2003;145(3):409‐17.

Bril 2010

Bril F, Gonzalez CD, Di Girolamo G. Antimicrobial agents‐associated with QT interval prolongation. Current Drug Safety 2010;5(1):85‐92.

Brodala 2005

Brodala N, Merricks EP, Bellinger DA, Damrongsri D, Offenbacher S, Beck J, et al. Porphyromonas gingivalis bacteremia induces coronary and aortic atherosclerosis in normocholesterolemic and hypercholesterolemic pigs. Arteriosclerosis, Thrombolysis, and Vascular Biology 2005;25(7):1446‐51.

Brok 2008

Brok J, Thorlund K, Gluud C, Wetterslev J. Trial Sequential Analysis reveals insufficient information size and potentially false positive results in many meta‐analyses. Journal of Clinical Epidemiology 2008;61(8):763‐9.

Brok 2009

Brok J, Thorlund K, Wetterslev J, Gluud C. Apparently conclusive meta‐analyses may be inconclusive‐‐Trial Sequential Analysis adjustment of random error risk due to repetitive testing of accumulating data in apparently conclusive neonatal meta‐analyses. International Journal of Epidemiology 2009;38(1):287‐98.

Burnett 2001

Burnett MS, Gaydos CA, Madico GE, Glad SM, Paigen B, Quinn TC, et al. Atherosclerosis in apoE knockout mice infected with multiple pathogens. Journal of Infectious Diseases 2001;183(2):226‐31.

Cannon 2005

Cannon CP, Braunwald E, McCabe CH, Grayston JT, Muhlestein B, Giugliano RP, et al. Antibiotic treatment of Chlamydia pneumoniae after acute coronary syndrome. New England Journal of Medicine 2005;352(16):1646‐54.

Cheng 2015

Cheng YJ, Nie XY, Chen XM, Lin XX, Tang K, Zeng WT, et al. The role of macrolide antibiotics in increasing cardiovascular risk. Journal of the American College of Cardiology 2015;66(20):2173‐84.

Chirgwin 1989

Chirgwin K, Roblin PM, Hammerschlag MR. In vitro susceptibilities of Chlamydia pneumoniae (Chlamydia sp. strain TWAR). Antimicrobial Agents and Chemotherapy 1989;33(9):1634‐5.

Dalhoff 2003

Dalhoff A, Shalit I. Immunomodulatory effects of quinolones. The Lancet Infectious Diseases 2003;3(6):359‐71.

Danesh 1997

Danesh J, Collins R, Peto R. Chronic infections and coronary heart disease: is there a link?. Lancet 1997;350(9075):430‐6.

Danesh 1998

Danesh J, Peto R. Risk factors for coronary heart disease and infection with Helicobacter pylori: meta‐analysis of 18 studies. BMJ 1998;316(7138):1130‐2.

Danesh 2000a

Danesh J, Whincup P, Walker M, Lennon L, Thomson A, Appleby P, et al. Low grade inflammation and coronary heart disease: prospective study and updated meta‐analyses. BMJ 2000;321(7255):199‐204.

Danesh 2000b

Danesh J, Whincup P, Walker M, Lennon L, Thomson A, Appleby P, et al. Chlamydia pneumoniae IgG titres and coronary heart disease: prospective study and meta‐analysis. BMJ 2000;321(7255):208‐13.

Danesh 2002

Danesh J, Whincup P, Lewington S, Walker M, Lennon L, Thomson A, et al. Chlamydia pneumoniae IgA titres and coronary heart disease: prospective study and meta‐analysis. European Heart Journal 2002;23(5):371‐5.

De Boer 2014

De Boer SP, Cheng JM, Range H, Garcia‐Garcia HM, Heo JH, Akkerhuis KM, et al. Antibodies to periodontal pathogens are associated with coronary plaque remodeling but not with vulnerability or burden. Atherosclerosis 2014;237(1):84‐91.

Deeks 2017

Deeks JJ, Higgins JPT, Altman DG (editors) on behalf of the Cochrane Statistical Methods Group. Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017), Cochrane, 2017. Available from www.training.cochrane.org/handbook.

DeMets 1987

DeMets DL. Methods for combining randomized clinical trials: strengths and limitations. Statistics in Medicine 1987;6(3):341‐50.

DerSimonian 1986

DerSimonian R, Laird N. Meta‐analysis in clinical trials. Controlled Clinical Trials 1986;7(3):177‐88.

Eckel 2014

Eckel RH, Jakicic JM, Ard JD, de Jesus JM, Houston Miller N, Hubbard VS, et al. 2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014;129(25 Suppl 2):S76‐99.

Egger 1997

Egger M, Davey‐Smith G, Schneider M, Minder C. Bias in meta‐analysis detected by a simple, graphical test. BMJ 1997;315(7109):629‐34.

Elbourne 2002

Elbourne DR,  Altman DG,  Higgins JP,  Curtin F,  Worthington HV,  Vail A. Meta‐analyses involving cross‐over trials: methodological issues. International Journal of Epidemiology 2002;31(1):140‐9.

Etminan 2004

Etminan M, Carleton B, Delaney JA, Padwal R. Macrolide therapy for Chlamydia pneumoniae in the secondary prevention of coronary artery disease: a meta‐analysis of randomized controlled trials. Pharmacotherapy 2004;24(3):338‐43.

Ezzahiri 2002

Ezzahiri R, Nelissen‐Vrancken HJ, Kurvers HA, Stassen FR, Vliegen I, Grauls GE, et al. Chlamydophila pneumoniae (Chlamydia pneumoniae) accelerates the formation of complex atherosclerotic lesions in Apo E3‐Leiden mice. Cardiovascular Research 2002;56(2):269‐76.

Ezzahiri 2003

Ezzahiri R, Stassen FR, Kurvers HA, Van Pul MM, Kitslaar PJ, Bruggeman CA. Chlamydia pneumoniae infection induces an unstable atherosclerotic plaque phenotype in LDL‐receptor, ApoE double knockout mice. European Journal of Vascular and Endovascular Surgery 2003;26(1):88‐95.

Ferreira‐Gonzalez 2014

Ferreira‐Gonzalez I. The epidemiology of coronary heart disease. Revista Espanola de Cardiologia (English Edition) 2014;67(2):139‐44.

Fihn 2012

Fihn SD, Gardin JM, Abrams J, Berra K, Blankenship JC, Dallas AP, et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Journal of the American College of Cardiology 2012;60(24):e44‐e164.

Filardo 2015

Filardo S, Di Pietro M, Farcomeni A, Schiavoni G, Sessa R. Chlamydia pneumoniae‐mediated inflammation in atherosclerosis: a meta‐analysis. Mediators of Inflammation 2015;2015:378658.

Folsom 1998

Folsom AR, Nieto FJ, Sorlie P, Chambless LE, Graham DY. Helicobacter pylori seropositivity and coronary heart disease incidence. Atherosclerosis Risk In Communities (ARIC) Study Investigators. Circulation 1998;98(9):845‐50.

Gaetti‐Jardim 2009

Gaetti‐Jardim E, Marcelino SL, Feitosa AC, Romito GA, Avila‐Campos MJ. Quantitative detection of periodontopathic bacteria in atherosclerotic plaques from coronary arteries. Journal of Medical Microbiology 2009;58(Pt 12):1568‐75.

Gaynor 2003

Gaynor M, Mankin AS. Macrolide antibiotics: binding site, mechanism of action, resistance. Current Topics in Medicinal Chemistry 2003;3(9):949‐61.

Gluud 2006

Gluud LL. Bias in clinical intervention research. American Journal of Epidemiology 2006;163(6):493‐501.

Gluud 2008

Gluud C, Als‐Nielsen B, Damgaard M, Fischer Hansen J, Hansen S, Helø OH, et al. CLARICOR Trial Group. Clarithromycin for 2 weeks for stable coronary heart disease: 6‐year follow‐up of the CLARICOR randomized trial and updated meta‐analysis of antibiotics for coronary heart disease. Cardiology 2008;111(4):280‐7.

Gotsman 2007

Gotsman I, Lotan C, Soskolne WA, Rassovsky S, Pugatsch T, Lapidus L, et al. Periodontal destruction is associated with coronary artery disease and periodontal infection with acute coronary syndrome. Journal of Periodontology 2007;78(5):849‐58.

GRADEpro GDT 2015 [Computer program]

McMaster University (developed by Evidence Prime). GRADEpro GDT. Version accessed 10 August 2015. Hamilton (ON): McMaster University (developed by Evidence Prime), 2015.

Grayston 2005

Grayston JT, Kronmal RA, Jackson LA, Parisi AF, Muhlestein JB, Cohen JD, et al. Azithromycin for the secondary prevention of coronary events. New England Journal of Medicine 2005;352(16):1637‐45.

Gupta 1997

Gupta S, Leatham EW, Carrington D, Mendall MA, Kaski JC, Camm AJ. Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction. Circulation 1997;96(2):404‐7.

Gurfinkel 1999

Gurfinkel E, Bozovich G, Beck E, Testa E, Livellara B, Mautner B. Treatment with the antibiotic roxithromycin in patients with acute non‐Q‐wave coronary syndromes. The final report of the ROXIS Study. European Heart Journal 1999;20(2):121‐7.

Guyatt 2008

Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck‐Ytter Y, Alonso‐Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336(7650):924‐6.

Guyatt 2011

Guyatt GH, Oxman AD, Schunemann HJ, Tugwell P, Knottnerus A. GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology. Journal of Clinical Epidemiology 2011;64(4):380‐2.

Harbord 2006

Harbord RM, Egger M, Sterne JA. A modified test for small‐study effects in meta‐analyses of controlled trials with binary endpoints. Statistics in Medicine 2006;25(20):3443‐57.

Higgins 2002

Higgins JP, Thompson SG. Quantifying heterogeneity in a meta‐analysis. Statistics in Medicine 2002;21(11):1539‐58.

Higgins 2003

Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta‐analyses. BMJ 2003;327(7414):557‐60.

Higgins 2011a

Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.

Higgins 2011b

Higgins JPT, Deeks JJ, Altman DG (editors). Chapter 16: Special topics in statistics. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.

Higgins 2017

Higgins JPT, Altman DG, Sterne JAC (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017), Cochrane, 2017. Available from www.training.cochrane.org/handbook.

Hizo‐Abes 2013

Hizo‐Abes P, Clark WF, Sontrop JM, Young A, Huang A, Thiessen‐Philbrook H, et al. Cardiovascular disease after Escherichia coli O157:H7 gastroenteritis. Canadian Medical Association Journal 2013;185(1):E70‐7.

ICH‐GCP 1997

ICH‐GCP. 1997 CFR & ICH Guidelines. International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. ICH harmonised tripartite guideline. Guideline for good clinical practice. 1. Vol. 1, PA 19063‐2043, USA: Barnett International/PAREXEL, 1997.

Imberger 2015

Imberger G, Gluud C, Boylan J, Wetterslev J. Systematic reviews of anesthesiologic interventions reported as statistically significant: problems with power, precision, and type 1 error protection. Anesthesia & Analgesia 2015;121(6):1611‐22.

Imberger 2016

Imberger G, Thorlund K, Gluud C, Wetterslev J. False‐positive findings in Cochrane meta‐analyses with and without application of Trial Sequential Analysis: an empirical review. BMJ Open 2016;6(8):e011890.

Jakobsen 2014

Jakobsen JC, Wetterslev J, Winkel P, Lange T, Gluud C. Thresholds for statistical and clinical significance in systematic reviews with meta‐analytic methods. BMC Medical Research Methodology 2014;14:120.

Jakobsen 2016

Jakobsen JC, Wetterslev J, Lange T, Gluud C. Viewpoint: taking into account risks of random errors when analysing multiple outcomes in systematic reviews. Cochrane Database of Systematic Reviews 2016;3:Ed000111.

Jensen 2010

Jensen GB, Hilden J, Als‐Nielsen B, Damgaard M, Hansen JF, Hansen S, et al. Statin treatment prevents increased cardiovascular and all‐cause mortality associated with clarithromycin in patients with stable coronary heart disease. Journal of Cardiovascular Pharmacology 2010;55(2):123‐8.

Jespersen 2006

Jespersen CM, Als‐Nielsen B, Damgaard M, Hansen JF, Hansen S, Helo OH, et al. Randomised placebo controlled multicentre trial to assess short term clarithromycin for patients with stable coronary heart disease: CLARICOR trial. BMJ 2006;332(7532):22‐7.

Jiang 2017

Jiang J, Chen Y, Shi J, Song C, Zhang J, Wang K. Population attributable burden of Helicobacter pylori‐related gastric cancer, coronary heart disease, and ischemic stroke in China. European Journal of Clinical Microbiology & Infectious Diseases 2017;36(2):199‐212.

Jin 2007

Jin SW, Her SH, Lee JM, Yoon HJ, Moon SJ, Kim PJ, et al. The association between current Helicobacter pylori infection and coronary artery disease. Korean Journal of Internal Medicine 2007;22(3):152‐6.

Kaptoge 2010

Kaptoge S, Di Angelantonio E, Lowe G, Pepys MB, Thompson SG, Collins R, et al. C‐reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta‐analysis. Lancet 2010;375(9709):132‐40.

Kazar 2005

Kazar J,  Kovacova E,  Koncova K,  Cvachova S,  Mongiellova V,  Lietava J,  et al. Chlamydia pneumoniae antibodies and markers of inflammation in patients with cardiovascular diseases. Bratislavské Lekárske Listy 2005;106(11):341‐4.

Keus 2010

Keus F, Wetterslev J, Gluud C, Van Laarhoven CJ. Evidence at a glance: error matrix approach for overviewing available evidence. BMC Medical Research Methodology 2010;10(90):1‐14.

Kjaergard 2001

Kjaergard LL, Villumsen J, Gluud C. Reported methodological quality and discrepancies between small and large randomized trials in meta‐analyses. Annals of Internal Medicine 2001;135:982‐9.

Kuo 1993

Kuo CC, Gown AM, Benditt EP, Grayston JT. Detection of Chlamydia pneumoniae in aortic lesions of atherosclerosis by immunocytochemical stain. Arteriosclerosis and Thrombosis 1993;13(10):1501‐4.

Lawson 2016

Lawson JS. Multiple Infectious Agents and the Origins of Atherosclerotic Coronary Artery Disease. Frontiers in Cardiovascular Medicine 2016;3:30.

Lefebvre 2011

Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching for studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.

Lenzi 2006

Lenzi C,  Palazzuoli A,  Giordano N,  Alegente G,  Gonnelli C,  Campagna MS,  et al. H pylori infection and systemic antibodies to CagA and heat shock protein 60 in patients with coronary heart disease. World Journal of Gastroenterology 2006;12(48):7815‐20.

Libby 2002

Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002;105(9):1135‐43.

Libby 2010

Libby P, Okamoto Y, Rocha VZ, Folco E. Inflammation in atherosclerosis: transition from theory to practice. Circulation Journal 2010;74(2):213‐20.

Libby 2011

Libby P, Ridker PM, Hansson GK. Progress and challenges in translating the biology of atherosclerosis. Nature 2011;473(7347):317‐25.

Linnanmaki 1993

Linnanmaki E, Leinonen M, Mattila K, Nieminen MS, Valtonen V, Saikku P. Chlamydia pneumoniae‐specific circulating immune complexes in patients with chronic coronary heart disease. Circulation 1993;87(4):1130‐4.

Lundh 2017

Lundh A, Lexchin J, Mintzes B, Schroll JB, Bero L. Industry sponsorship and research outcome. Cochrane Database of Systematic Reviews 2017;2:Mr000033.

Maekawa 2011

Maekawa T, Takahashi N, Tabeta K, Aoki Y, Miyashita H, Miyauchi S, et al. Chronic oral infection with Porphyromonas gingivalis accelerates atheroma formation by shifting the lipid profile. PLoS One 2011;6(5):e20240.

Mahdi 2002

Mahdi OS, Horne BD, Mullen K, Muhlestein JB, Byrne GI. Serum immunoglobulin G antibodies to chlamydial heat shock protein 60 but not to human and bacterial homologs are associated with coronary artery disease. Circulation 2002;106(13):1659‐63.

Mahendra 2009

Mahendra J, Mahendra L, Kurian VM, Jaishankar K, Mythilli R. Prevalence of periodontal pathogens in coronary atherosclerotic plaque of patients undergoing coronary artery bypass graft surgery. Journal of Maxillofacial and Oral Surgery 2009;8(2):108‐13.

Mahendra 2015

Mahendra J, Mahendra L, Nagarajan A, Mathew K. Prevalence of eight putative periodontal pathogens in atherosclerotic plaque of coronary artery disease patients and comparing them with noncardiac subjects: a case‐control study. Indian Journal of Dental Research 2015;26(2):189‐95.

Malfertheiner 2007

Malfertheiner P, Megraud F, O'Morain C, Bazzoli F, El‐Omar E, Graham D, et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 2007;56(6):772‐81.

Matusiak 2016

Matusiak A, Chalubinski M, Broncel M, Rechcinski T, Rudnicka K, Miszczyk E, et al. Putative consequences of exposure to Helicobacter pylori infection in patients with coronary heart disease in terms of humoral immune response and inflammation. Archives of Medical Science 2016;12(1):45‐54.

Mendall 1994

Mendall MA, Goggin PM, Molineaux N, Levy J, Toosy T, Strachan D, et al. Relation of Helicobacter pylori infection and coronary heart disease. British Heart Journal 1994;71(5):437‐9.

Mendall 1996

Mendall MA, Patel P, Ballam L, Strachan D, Northfield TC. C reactive protein and its relation to cardiovascular risk factors: a population based cross sectional study. BMJ 1996;312(7038):1061‐5.

Moher 1998

Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta‐analyses?. Lancet 1998;352(9128):609‐13.

Moher 2009

Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta‐analyses: the PRISMA statement. Journal of Clinical Epidemiology 2009;62(10):1006‐12.

Montalescot 2013

Montalescot G, Sechtem U, Achenbach S, Andreotti F, Arden C, Buday A, et al. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. European Heart Journal2013; Vol. 34, issue 38:2949‐3003.

Mozaffarian 2016

Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, et al. Heart Disease and Stroke Statistics‐2016 Update: a report from the American Heart Association. Circulation 2016;133(4):e38‐360.

Muhlestein 1996

Muhlestein JB, Hammond EH, Carlquist JF, Radicke E, Thomson MJ, Karagounis LA, et al. Increased incidence of Chlamydia species within the coronary arteries of patients with symptomatic atherosclerotic versus other forms of cardiovascular disease. Journal of the American College of Cardiology 1996;27(7):1555‐61.

Norman 2003

Norman GR, Sloan JA, Wyrwich KW. Interpretation of changes in health‐related quality of life: the remarkable universality of half a standard deviation. Medical Care 2003;41(5):582‐92.

Pesonen 2009

Pesonen E, El‐Segaier M, Persson K, Puolakkainen M, Sarna S, Ohlin H, et al. Infections as a stimulus for coronary occlusion, obstruction, or acute coronary syndromes. Therapeutic Advances in Cardiovascular Diseases 2009;3(6):447‐54.

Piepoli 2016

Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: the Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts). Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). European Heart Journal 2016;37(29):2315‐81.

Pigarevskii 2015

Pigarevskii PV, Mal'tseva SV, Snegova VA, Davydova NG, Guseva VA. Chlamydia pneumoniae and immunoinflammatory reactions in an unstable atherosclerotic plaque in humans. Bulletin of Experimental Biology and Medicine 2015;159(2):278‐81.

Polk 1999

Polk R. Optimal use of modern antibiotics: emerging trends. Clinical Infectious Diseases 1999;29(2):264‐74.

Prasad 2002

Prasad A, Zhu J, Halcox JP, Waclawiw MA, Epstein SE, Quyyumi AA. Predisposition to atherosclerosis by infections: role of endothelial dysfunction. Circulation 2002;106(2):184‐90.

Pucar 2007

Pucar A, Milasin J, Lekovic V, Vukadinovic M, Ristic M, Putnik S, et al. Correlation between atherosclerosis and periodontal putative pathogenic bacterial infections in coronary and internal mammary arteries. Journal of Periodontology 2007;78(4):677‐82.

Pussinen 2004

Pussinen PJ, Alfthan G, Tuomilehto J, Asikainen S, Jousilahti P. High serum antibody levels to Porphyromonas gingivalis predict myocardial infarction. European Journal of Cardiovascular Prevention and Rehabilitation 2004;11(5):408‐11.

Rajagopalan 1996

Rajagopalan S, Meng XP, Ramasamy S, Harrison DG, Galis ZS. Reactive oxygen species produced by macrophage‐derived foam cells regulate the activity of vascular matrix metalloproteinases in vitro. Implications for atherosclerotic plaque stability. Journal of Clinical Investigation 1996;98(11):2572‐9.

Renvert 2006

Renvert S, Pettersson T, Ohlsson O, Persson GR. Bacterial profile and burden of periodontal infection in subjects with a diagnosis of acute coronary syndrome. Journal of Periodontology 2006;77(7):1110‐9.

RevMan 2014 [Computer program]

Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.

Ridker 1999

Ridker PM, Kundsin RB, Stampfer MJ, Poulin S, Hennekens CH. Prospective study of Chlamydia pneumoniae IgG seropositivity and risks of future myocardial infarction. Circulation 1999;99(9):1161‐4.

Roivainen 2000

Roivainen M, Viik‐Kajander M, Palosuo T, Toivanen P, Leinonen M, Saikku P, et al. Infections, inflammation, and the risk of coronary heart disease. Circulation 2000;101(3):252‐7.

Romano Carratelli 2006

Romano Carratelli C,  Nuzzo I,  Cozzolino D,  Bentivoglio C,  Paolillo R,  Rizzo A. Relationship between Chlamydia pneumoniae infection, inflammatory markers, and coronary heart diseases. International Immunopharmacology 2006;6(5):848‐53.

Rosenfeld 2011

Rosenfeld ME, Campbell LA. Pathogens and atherosclerosis: update on the potential contribution of multiple infectious organisms to the pathogenesis of atherosclerosis. Thrombosis and Haemostasis 2011;106(5):858‐67.

Ross 1999

Ross R. Atherosclerosis‐‐an inflammatory disease. NEJM 1999;340(2):115‐26.

Saikku 1988

Saikku P, Leinonen M, Mattila K, Ekman MR, Nieminen MS, Makela PH, et al. Serological evidence of an association of a novel Chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction. Lancet 1988;2(8618):983‐6.

Sakurai‐Komada 2014

Sakurai‐Komada N, Iso H, Koike KA, Ikeda A, Umesawa M, Ikehara S, et al. Association between Chlamydophila pneumoniae infection and risk of coronary heart disease for Japanese: the JPHC study. Atherosclerosis 2014;233(2):338‐42.

Sapadin 2006

Sapadin AN, Fleischmajer R. Tetracyclines: nonantibiotic properties and their clinical implications. Journal of the American Academy of Dermatology 2006;54(2):258‐65.

Savovic 2012

Savovic J, Jones HE, Altman DG, Harris RJ, Juni P, Pildal J, et al. Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials. Annals of Internal Medicine 2012;157(6):429‐38.

Schulz 1995

Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273(5):408‐12.

Schunemann 2003

Schunemann HJ, Best D, Vist G, Oxman AD. Letters, numbers, symbols and words: how to communicate grades of evidence and recommendations. Canadian Medical Association Journal 2003;169(7):677‐80.

Schunemann 2013

Schunemann HJ, Brozek J, Guyatt G, Oxman AD, editors. GRADE handbook for grading quality of evidence and strength of recommendation. Available from http://gdt.guidelinedevelopment.org/app/handbook/handbook.html. The Grade Working Group2013.

Schünemann 2017

Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, Akl E, Guyatt GH on behalf of the Cochrane Applicability and Recommendations Methods Group. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017). Cochrane, 2017. Available from www.training.cochrane.org/handbook.

Shmuely 2014

Shmuely H, Wattad M, Solodky A, Yahav J, Samra Z, Zafrir N. Association of Helicobacter pylori with coronary artery disease and myocardial infarction assessed by myocardial perfusion imaging. Israel Medicine Association Journal 2014;16(6):341‐6.

Shor 1992

Shor A, Kuo CC, Patton DL. Detection of Chlamydia pneumoniae in coronary arterial fatty streaks and atheromatous plaques. South African Medical Journal 1992;82(3):158‐61.

Smith 2011

Smith SC, Benjamin EJ, Bonow RO, Braun LT, Creager MA, Franklin BA, et al. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation endorsed by the World Heart Federation and the Preventive Cardiovascular Nurses Association. Journal of the American College of Cardiology 2011;58(23):2432‐46.

Spahr 2006

Spahr A, Klein E, Khuseyinova N, Boeckh C, Muche R, Kunze M, et al. Periodontal infections and coronary heart disease: role of periodontal bacteria and importance of total pathogen burden in the Coronary Event and Periodontal Disease (CORODONT) study. Archives of Internal Medicine 2006;166(5):554‐9.

Steel 2012

Steel HC, Theron AJ, Cockeran R, Anderson R, Charles F. Pathogen‐ and host‐directed anti‐inflammatory activities of macrolide antibiotics. Mediators of Inflammation2012.

Sun 2016

Sun J, Rangan P, Bhat SS, Liu L. A meta‐analysis of the association between Helicobacter pylori infection and risk of coronary heart disease from published prospective studies. Helicobacter 2016;21(1):11‐23.

Thom 1991

Thom DH, Wang SP, Grayston JT, Siscovick DS, Stewart DK, Kronmal RA, et al. Chlamydia pneumoniae strain TWAR antibody and angiographically demonstrated coronary artery disease. Arteriosclerosis and Thrombosis 1991;11(3):547‐51.

Thorlund 2009

Thorlund K, Devereaux PJ, Wetterslev J, Guyatt G, Ioannidis JP, Thabane L, et al. Can trial sequential monitoring boundaries reduce spurious inferences from meta‐analyses?. International Journal of Epidemiology 2009;38(1):276‐86.

Thorlund 2010

Thorlund K, Anema A, Mills E. Interpreting meta‐analysis according to the adequacy of sample size. An example using isoniazid chemoprophylaxis for tuberculosis in purified protein derivative negative HIV‐infected individuals. Journal of Clinical Epidemiology 2010;2:57‐66.

Thorlund 2011

Thorlund K, Imberger G, Walsh M, Chu R, Gluud C, Wetterslev J, et al. The number of patients and events required to limit the risk of overestimation of intervention effects in meta‐analysis ‐ a simulation study. PLoS One 2011;6(10):e25491.

Torgano 1999

Torgano G, Cosentini R, Mandelli C, Perondi R, Blasi F, Bertinieri G, et al. Treatment of Helicobacter pylori and Chlamydia pneumoniae infections decreases fibrinogen plasma level in patients with ischemic heart disease. Circulation 1999;99(12):1555‐9.

TSA 2011 [Computer program]

Copenhagen Trial Unit. Trial Sequential Analysis. Version 0.9 beta. Copenhagen: Copenhagen Trial Unit, 2011.

Turner 2013

Turner RM, Bird SM, Higgins JP. The impact of study size on meta‐analyses: examination of underpowered studies in Cochrane reviews. PLoS One 2013;8(3):e59202.

Vcev 2007

Vcev A, Nakic D, Mrden A, Mirat J, Balen S, Ruzic A, et al. Helicobacter pylori infection and coronary artery disease. Collegium Antropologicum 2007;31(3):757‐60.

Waksman 1947

Waksman SA. What is an antibiotic or an antibiotic substance?. Mycologia 1947;39(5):565‐9.

Wetterslev 2008

Wetterslev J, Thorlund K, Brok J, Gluud C. Trial sequential analysis may establish when firm evidence is reached in cumulative meta analysis. Journal of Clinical Epidemiology 2008;61:64‐75.

Wetterslev 2009

Wetterslev J, Thorlund K, Brok J, Gluud C. Estimating required information size by quantifying diversity in random‐effects model meta‐analyses. BMC Medical Research Methodology 2009;9:86.

Wetterslev 2017

Wetterslev J, Jakobsen JC, Gluud C. Trial Sequential Analysis in systematic reviews with meta‐analysis. BMC Medical Research Methodology 2017;17(1):39.

Whincup 1996

Whincup PH, Mendall MA, Perry IJ, Strachan DP, Walker M. Prospective relations between Helicobacter pylori infection, coronary heart disease, and stroke in middle aged men. Heart 1996;75(6):568‐72.

WHO 2011

Mendis S, Puska P, Norrving B (editors). Global Atlas on Cardiovascular Disease Prevention and Control. Geneva: World Health Organization, 2011.

WHO 2016

World Health organization. Cardiovascular diseases ‐ Fact sheet N 317. WHO ‐ Available from: www.who.int/mediacentre/factsheets/fs317/en/ Updated 2016 Jun; cited 2016 Aug 20].

Winkel 2011

Winkel P, Hilden J, Fischer Hansen J, Hildebrandt P, Kastrup J, Kolmos HJ, et al. Excess sudden cardiac deaths after short‐term clarithromycin administration in the CLARICOR trial: why is this so, and why are statins protective?. Cardiology 2011;118(1):63‐7.

Winkel 2015

Winkel P, Hilden J, Hansen JF, Kastrup J, Kolmos HJ, Kjoller E, et al. Clarithromycin for stable coronary heart disease increases all‐cause and cardiovascular mortality and cerebrovascular morbidity over 10 years in the CLARICOR randomised, blinded clinical trial. International Journal of Cardiology 2015;182:459‐65.

Wong 2014

Wong ND. Epidemiological studies of CHD and the evolution of preventive cardiology. Nature Reviews Cardiology 2014;11(5):276‐89.

Wood 2008

Wood L, Egger M, Gluud LL, Schulz KF, Juni P, Altman DG, et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta‐epidemiological study. BMJ 2008;336(7644):601‐5.

Zaremba 2007

Zaremba M, Gorska R, Suwalski P, Kowalski J. Evaluation of the incidence of periodontitis‐associated bacteria in the atherosclerotic plaque of coronary blood vessels. Journal of Periodontology 2007;78(2):322‐7.

Zhu 2001

Zhu J, Nieto FJ, Horne BD, Anderson JL, Muhlestein JB, Epstein SE. Prospective study of pathogen burden and risk of myocardial infarction or death. Circulation 2001;103(1):45‐51.

Zhu 2002

Zhu J, Quyyumi AA, Muhlestein JB, Nieto FJ, Horne BD, Zalles‐Ganley A, et al. Lack of association of Helicobacter pylori infection with coronary artery disease and frequency of acute myocardial infarction or death. American Journal of Cardiology 2002;89(2):155‐8.
Table 1. The Cochrane tool for assessing risk of bias

Domain

Description

Random sequence generation

  • Low risk: if sequence generation was achieved using computer random number generator or a random numbers table. Drawing lots, tossing a coin, shuffling cards, and throwing dice were also considered adequate if performed by an independent adjudicator.

  • Unclear risk: if the method of randomisation was not specified, but the trial was still presented as being randomised.

  • High risk: if the allocation sequence was not randomised or only quasi‐randomised. We will exclude these trials.

Allocation concealment

  • Low risk: if the allocation of participants was performed by a central independent unit, on‐site locked computer, identical‐looking numbered sealed envelopes, drug bottles, or containers prepared by an independent pharmacist or investigator.

  • Uncertain risk: if the trial was classified as randomised but the allocation concealment process was not described.

  • High risk: if the allocation sequence was familiar to the investigators who assigned participants.

Blinding of participants and personnel

  • Low risk: if the participants and the personnel were blinded to intervention allocation and this was described.

  • Uncertain risk: if the procedure of blinding was insufficiently described.

  • High risk: if blinding of participants and the personnel was not performed.

Blinding of outcome assessment

  • Low risk of bias: if it was mentioned that outcome assessors were blinded and this was described.

  • Uncertain risk of bias: if it was not mentioned if the outcome assessors in the trial were blinded, or the extent of blinding was insufficiently described.

  • High risk of bias: if no blinding or incomplete blinding of outcome assessors was performed.

Incomplete outcome data

  • Low risk of bias: if missing data were unlikely to make treatment effects depart from plausible values. This could either be: 1) there were no drop‐outs or withdrawals for all outcomes, or 2) the numbers and reasons for the withdrawals and drop‐outs for all outcomes were clearly stated and could be described as being similar in both groups. Generally, the trial is judged as at a low risk of bias due to incomplete outcome data if drop‐outs are less than 5%. However, the 5% cut‐off is not definitive.

  • Uncertain risk of bias: if there was insufficient information to assess whether missing data were likely to induce bias on the results.

  • High risk of bias: if the results were likely to be biased due to missing data either because the pattern of drop‐outs could be described as being different in the two intervention groups or the trial used improper methods in dealing with the missing data (e.g. last observation carried forward).

Selective outcome reporting

  • Low risk of bias: if a protocol was published before or at the time the trial was begun and the outcomes specified in the protocol were reported on. If there is no protocol or the protocol was published after the trial has begun, reporting of all‐cause mortality and serious adverse events will grant the trial a grade of low risk of bias.

  • Uncertain risk of bias: if no protocol was published and the outcomes all‐cause mortality and serious adverse events were not reported on.

  • High risk of bias: if the outcomes in the protocol were not reported on.

Other risks of bias

  • Low risk of bias: if the trial appears to be free of other components (for example, academic bias or for‐profit bias) that could put it at risk of bias.

  • Unclear risk of bias: if the trial may or may not be free of other components that could put it at risk of bias.

  • High risk of bias: if there are other factors in the trial that could put it at risk of bias (for example, authors have conducted trials on the same topic, for‐profit bias etc).

Overall risk of bias

  • Low risk of bias: the trial will be classified as overall 'low risk of bias' only if all of the bias domains described in the above paragraphs are classified as 'low risk of bias'.

  • High risk of bias: the outcome result will be classified 'high risk of bias' if any of the bias risk domains described in the above are classified as 'unclear' or 'high risk of bias'.

Figures and Tables -
Table 1. The Cochrane tool for assessing risk of bias